Shelton Capital Management Intellia Therapeutics, Inc. Transaction History

Shelton Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $97,056 - $129,060	-1,800 Reduced 2.64%	66,500 $3.72 Million
Q1 2020 May 13, 2020	BUY	$9.44 - $15.58 $161,424 - $266,418	17,100 Added 33.4%	68,300 $835,000
Q4 2019 Feb 11, 2020	BUY	$10.43 - $17.67 $119,945 - $203,205	11,500 Added 28.97%	51,200 $751,000
Q3 2019 Nov 13, 2019	BUY	$13.07 - $18.51 $196,050 - $277,650	15,000 Added 60.73%	39,700 $530,000
Q2 2019 Aug 14, 2019	BUY	$13.88 - $18.41 $339,754 - $450,639	24,478 Added 11026.13%	24,700 $404,000
Q1 2019 May 10, 2019	SELL	$12.79 - $17.62 $163,430 - $225,148	-12,778 Reduced 98.29%	222 $13 Million
Q2 2018 Aug 10, 2018	BUY	$20.02 - $30.79 $260,260 - $400,270	13,000 New	13,000 $356,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

Stay updated on Shelton Capital Management with notifications on news.